title: [Etiotropic therapy of influenza: lessons from the last pandemic].
abstract: Analysis of the experience gained during the last pandemic of 'swine' influenza A (H1N1) sw1 is presented with reference to clinical studies and etiotropic therapy. The mechanism of development of severe pneumonia as a result of mutations at the binding site of hemagglutinin receptor enhancing a2'-3'-sialoside specificity and pneumotropism of the virus is described. The data on the efficiency of Ingavirin, a new Russian antiviral for the treatment of influenza, are reported.
authors.forename: L V
authors.initials: LV
authors.lastname: Kolobukhina
authors.forename: M Iu
authors.initials: MIu
authors.lastname: Shchelkanov
authors.forename: L N
authors.initials: LN
authors.lastname: Merkulova
authors.forename: M V
authors.initials: MV
authors.lastname: Bazarova
authors.forename: E I
authors.initials: EI
authors.lastname: Burtseva
authors.forename: E I
authors.initials: EI
authors.lastname: Samokhvalov
authors.forename: S V
authors.initials: SV
authors.lastname: Al'khovskiĭ
authors.forename: A G
authors.initials: AG
authors.lastname: Prilipov
authors.forename: I T
authors.initials: IT
authors.lastname: Fediakina
authors.forename: E S
authors.initials: ES
authors.lastname: Proshina
authors.forename: V A
authors.initials: VA
authors.lastname: Aristova
authors.forename: T N
authors.initials: TN
authors.lastname: Morozova
authors.forename: O A
authors.initials: OA
authors.lastname: Sutochnikova
authors.forename: R A
authors.initials: RA
authors.lastname: Ponomarenko
authors.forename: N A
authors.initials: NA
authors.lastname: Malyshev
authors.forename: A M
authors.initials: AM
authors.lastname: Maslov
authors.forename: A G
authors.initials: AG
authors.lastname: Chuchalin
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects; D021821:Communicable Diseases, Emerging / Q000821:virology; D024882:Drug Resistance, Viral; D042241:Early Diagnosis; D006387:Hemagglutination, Viral / Q000235:genetics; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000187:drug effects / Q000472:pathogenicity / Q000502:physiology; D007252:Influenza Vaccines / Q000627:therapeutic use; D007251:Influenza, Human / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology* / Q000821:virology; D053139:Oseltamivir / Q000008:administration & dosage / Q000009:adverse effects; D058873:Pandemics / Q000517:prevention & control; D011024:Pneumonia, Viral / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology / Q000821:virology; D011379:Prognosis; D012720:Severity of Illness Index; D014762:Viral Interference; D056189:Viral Tropism / Q000235:genetics*; D053243:Zanamivir / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D000998:Antiviral Agents; D007252:Influenza Vaccines; D053139:Oseltamivir; D053243:Zanamivir